Medium urgency

Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability

Detected September 2, 2026 · in Pharmacy & Controlled Substances

FDA has released draft guidance on pharmacokinetics in patients with impaired hepatic function, impacting dosage considerations for controlled substances.

Aforeworn detected this change in the Pharmacy & Controlled Substances space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmacy & Controlled Substances move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.

What changed

New guidance on study design and data analysis for dosage adjustments in patients with liver impairment.

Who it affects

Independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies.

What you must do

Review the draft guidance and adjust prescribing practices for affected patients accordingly.

Deadline

N/A

Source: https://www.federalregister.gov/documents/2026/09/02/2026-17961/pharmacokinetics-in-patients-with-impaired-hepatic-function-study-design-data-analysis-and-impact-on

Never miss a change like this again

Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmacy & Controlled Substances